Frequently bought together

WEGOVY 0.5 MG INJECTION

481.45

Sku : I-033614
Key features
WEGOVY 0.5 mg injection is a solution for injection in a pre-filled pen containing semaglutide 0.5 mg. It is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist that enhances glucose‑dependent insulin secretion, reduces inappropriate glucagon release, slows gastric emptying and suppresses appetite via central pathways. WEGOVY is indicated for chronic weight management as an adjunct to a reduced‑calorie diet and increased physical activity in adults with obesity, adults with overweight plus at least one weight‑related comorbidity, and pediatric patients aged 12 years and older with obesity; it is also approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight. Available by prescription as a 4‑dose pre-filled pen for subcutaneous administration.
- Active Ingredient: SEMAGLUTIDE 0.5mg
- Strength: 0.5mg
- Dosage Form: Solution for injection in pre-filled pen
- Pack Size: 4 dose
- Route: Subcutaneous use
- Prescription Status: Prescription
- Therapeutic Class: Antidiabetic
- Pharmacological Group: GLP-1 Receptor Agonists
- Drug Class: GLP-1 Receptor Agonist (Glucagon-Like Peptide-1 Receptor Agonist), long-acting subcutaneous formulation
- Manufacturer: NOVO NORDISK
- Country of Origin: Denmark
- SFDA Registration No.: 2101256698
- Shelf Life: 36 months
- Storage: store in a refrigerator (2°c - 8°c)
- Diabetes Type: Type 2

Frequently bought together

Description

Specification

Indications

Approved Uses

Chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity: (1) adults with obesity, or overweight with at least one weight-related comorbidity; and (2) pediatric patients aged 12 years and older with obesity. Also approved to reduce the risk of major adverse cardiovascular events (CV death, nonfatal MI, nonfatal stroke) in adults with established cardiovascular disease and either obesity or overweight.

Dosage & Administration

Dosing by Condition

For Wegovy indications (weight management and cardiovascular risk reduction): 0.25 mg SC once weekly for 4 weeks, then 0.5 mg for 4 weeks, then 1 mg for 4 weeks, then 1.7 mg for 4 weeks, then maintenance 2.4 mg once weekly (or 1.7 mg if 2.4 mg not tolerated).

Maintenance Dose

1.7 mg or 2.4 mg subcutaneously once weekly.

Maximum Dose

2.4 mg subcutaneously once weekly.

Pharmacology

Mechanism of Action

GLP-1 receptor agonist that increases glucose-dependent insulin secretion, decreases inappropriate glucagon secretion, slows gastric emptying, and reduces appetite/energy intake via central pathways.

Duration of Effect

Approximately 7 days, supporting once-weekly dosing.

Half-Life

Approximately 1 week (~7 days; about 165-184 hours).

Bioavailability

Approximately 89% (subcutaneous absolute bioavailability).

Metabolism

Metabolized by proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty-acid side chain; not meaningfully metabolized by CYP450 enzymes.